Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avadaforce is a combination pharmaceutical product containing avanafil and dapoxetine. Avanafil is a selective phosphodiesterase type 5 (PDE5) inhibitor that facilitates penile erection by increasing blood flow through the inhibition of cGMP degradation. Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) used to treat premature ejaculation by increasing the time to ejaculation and improving control over ejaculation. This combination is typically used to treat male sexual dysfunction involving both erectile dysfunction and premature ejaculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avanafil + dapoxetine.